females to follow finalist
RISING STAR IN ENTREPRENEURSHIP
Hanne Callewaert
Chief Executive Officer & Co-Founder
AstriVax Therapeutics
About Hanne Callewaert
Hanne has 20+ years experience in life
science industry, with senior roles in pharma (GSK) and biotech companies
(Oxurion, Oncurious, AstriVax Therapeutics). As co-founder and CEO of AstriVax
Therapeutics, she was key in securing 35 million euros in financing to start-up
and scale-up AstriVax Therapeutics from academic technology to clinical stage
company. AstriVax Therapeutics develops immunotherapy assets to treat chronic
viral infections through its Launch-iT platform. Hanne has a strong background
in regulatory affairs, drug and vaccine development and IP and has a proven
track in building teams and creating a company culture in which teams can
excel. She holds a Master in Biomedical Sciences, a PhD in Medical Sciences and
a Master in IP and beyond being a dedicated CEO, she loves sports, good food,
traveling and is, last but not least, proud mom of 4 children between 12 and 19
years old.
About AstriVax Therapeutics
AstriVax
Therapeutics is a European based, clinical-stage biopharmaceutical company,
founded in 2022 with a strong focus on immunotherapies. The company develops
immunotherapy assets by launching self-amplifying live attenuated viral vectors
and target antigens, through the Launch-iT platform. We differentiate in the
ability to create qualitative effector T-cells with a unique durable profile.
We focus on treating early, clearing infections and hence preventing
progression into cancer for e.g. HPV. Our future pipeline could encompass
oncology and autoimmune diseases as well.
AstriVax
Therapeutics is a European based, clinical-stage biopharmaceutical company,
founded in 2022 with a strong focus on immunotherapies. The company develops
immunotherapy assets by launching self-amplifying live attenuated viral vectors
and target antigens, through the Launch-iT platform. We differentiate in the
ability to create qualitative effector T-cells with a unique durable profile.
We focus on treating early, clearing infections and hence preventing
progression into cancer for e.g. HPV. Our future pipeline could encompass
oncology and autoimmune diseases as well.
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects